title: Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
abstract: BACKGROUND
  Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure.
  
  
  OBJECTIVE
  To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study population.
  
  
  METHODS
  Adults from Ciudad Juarez with H. pylori infections identified by culture or histology received rabeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g, each b.d. for 7 days. Outcome was assessed by 13C-urea breath test carried out 4+ weeks after treatment.
  
  
  RESULTS
  A total of 111 patients were enrolled and evaluated by urea breath test; 102 completed the full 7 days therapy. Two deviated from protocol, and five stopped because of adverse events. The cure rate (intention-to-treat) was 85% (95% CI: 78-91%); the per-protocol cure rate was 85% (95% CI: 78-91%). Side-effects were not serious and only 6.6% of those with adverse events stopped medication. Only three isolates were clarithromycin-resistant and none was cured. Compliance explained most of the successes.
  
  
  CONCLUSIONS
  In the study population a 7-day rabeprazole triple eradication therapy was both effective and well-tolerated. Clarithromycin resistance was uncommon. We observed a slightly better outcome but consistent with results from recent large studies in US populations.
authors.affiliation: El Paso Regional Campus, University of Texas School of Public Health, El Paso, TX 79902, USA. victor.cardenas@uth.tmc.edu
authors.forename: V M
authors.initials: VM
authors.lastname: Cardenas
authors.forename: D Y
authors.initials: DY
authors.lastname: Graham
authors.forename: H M T
authors.initials: HM
authors.lastname: El-Zimaity
authors.forename: A R
authors.initials: AR
authors.lastname: Opekun
authors.forename: A
authors.initials: A
authors.lastname: Campos
authors.forename: A
authors.initials: A
authors.lastname: Chavez
authors.forename: L
authors.initials: L
authors.lastname: Guerrero
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010349:Patient Compliance; D010865:Pilot Projects; D064750:Rabeprazole; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole